GeneDx Holdings Corp. (WGS)
Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.
NasdaqGS · Price as of · Nasdaq Real Time Price
- Profitability0/20
Losing money: $-111.0M net income over the last four reported quarters. Revenue over the last four reported quarters was $460.8M, up 15% from $402.2M the year before.
- Insider buying vs selling20/20
Insiders are net buyers: 2 open-market buys worth $11.1M vs 22 sells worth $3.0M across the last 20 Form 4 filings.
- Dilution and offerings6/15
Share count up 3.7% in a year. Real dilution.
- Analysts8
- Implied upside+67.7%
- Target range$80.00 to $103.00
WGS closed at $56.75 on Nov 10, down 11.1% since Oct 12. Chart read: price below both the 50-day and 200-day moving averages; the 50-day is above the 200-day (uptrend structure); trading at 17% of the 52-week range ($34.51 to $167.51).
Insider buying and selling at GeneDx Holdings Corp. (WGS)
The most recent Form 4 on record for GeneDx Holdings Corp. (WGS) is September 16, 2026, when Katherine Stueland, CHIEF EXECUTIVE OFFICER, sold $1.0M of stock. Those shares went automatically to cover tax on a vest, so it was not a decision to sell.
| Insider | Action | Value | Date | Type |
|---|---|---|---|---|
| Katherine Stueland · CHIEF EXECUTIVE OFFICER | Sell | $1.0M | September 16, 2026 | No decision |
| Kevin Feeley · CHIEF FINANCIAL OFFICER | Sell | $363,892 | September 16, 2026 | No decision |
| Katherine Stueland · CHIEF EXECUTIVE OFFICER | Sell | $310,932 | September 9, 2026 | No decision |
Filed notices to sell
A Form 144 is filed beforean insider sells restricted stock. The Form 4 reporting the completed trade isn't due until two business days after the sale, so these land first. They are intentions, not transactions.
| Insider | Value | Filed | Status | Type |
|---|---|---|---|---|
| Feeley Kevin · Officer | $458,500 | September 1, 2026 | Executed | Vested shares |
| Stueland Katherine · Officer, Director | $1.2M | September 1, 2026 | Executed | Vested shares |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 10-Q | November 9, 2026 | 10-Q |
| 8-K | November 9, 2026 | 8-K |
| SCHEDULE 13G | November 6, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 11, 2026 | View on EDGAR |
| 4 | September 11, 2026 | View on EDGAR |
GeneDx news
Frequently asked questions
What do analysts expect for WGS?
8 analysts cover GeneDx Holdings Corp. (WGS). The consensus rating is Strong buy. The average price target is $91.00, in a range of $80.00 to $103.00.
Are insiders buying or selling WGS?
We track Form 4 filings for GeneDx Holdings Corp. (WGS). The activity listed on this page shows 3 qualifying sales. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.
Where can I see WGS SEC filings?
Recent filings are listed on this page, newest first. The latest is a 10-Q filed November 9, 2026.